ALK2 and JAK2 Inhibition for Improved Treatment of Anemia in Myelofibrosis Patients: Preclinical Profile of an ALK2 Inhibitor Zilurgisertib in Combination with RuxolitinibMatthew C. Stubbs,Michelle Pusey,Xiaoming Wen,Katherine Drake,Nina Zolotarjova, Amanda Smith,Maryanne Covington,Guofeng Zhang, Ricardo Macarron, Sunkyu KimBLOOD(2023)引用 0|浏览6暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要